Interestingly, in a study in RA patients in which all patients were treated with methotrexate (MTX), treatment with denosumab, a monoclonal antibody against RANKL, versus placebo, reduced joint damage [33]. The gene discussed is TNFSF11; the disease is rheumatoid arthritis.